Hospital Mater Dei (MATD3) Q4 2024 earnings summary

Executive summary

• 2024 was marked by macroeconomic and sector-specific challenges, prompting strategic adjustments, operational agreements, and new service launches to strengthen financial robustness and future growth.

• Leadership and resilience were maintained in the Belo Horizonte region, with revenue growth and operational improvements despite industry challenges.

• New hospital openings, such as Nova Lima, and partnerships like the Uberlândia-Unimed agreement, are expected to drive future volume and profitability.

• Corporate restructuring, including personnel cuts and asset sales, improved cash position and reduced costs.

• Recertified as a Great Place to Work and recognized for mental health initiatives.

Financial highlights

• Net revenue for 2024 grew 1.8% year-over-year to BRL 2,226 million; company-wide revenue up 2%, with Belo Horizonte up 7%.

• Adjusted EBITDA for 2024 was BRL 459 million (20.6% margin), down 12.7% year-over-year; Q4 2024 EBITDA margin was 15.9%.

• Net income for 2024 was BRL 196 million (8.8% margin), down 7.9% year-over-year.

• Cash and equivalents at year-end were BRL 675 million, up 112% from the previous year.

• Net debt/EBITDA at 1.5x as of 4Q24; net debt at BRL 1,447 million.

Outlook and guidance

• 2025 is expected to benefit from operational improvements, cost reductions, and ramp-up of new units, with a focus on restoring margins and cash generation.

• CapEx for 2025 is projected to be significantly lower than 2024, as major investments have already been made.

• Robotic surgery to launch at Hospital Santa Clara in March 2025, expanding high-complexity services.

• Ongoing expansion with new units under construction, including Mater Dei São Paulo.

• Anticipated margin normalization and improved profitability from Q2 2025 onward, driven by cost discipline and efficiency initiatives.